Interferon therapy for ocular disease

Current Opinion in Ophthalmology

Volumn 17, Issue 6, 2006, Pages 567-573

  Mackensen, Friederike ^a   Max, Regina ^a   Becker, Matthias D ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Interdisciplinary Uveitis Center   (Germany)

Author keywords

Interferon; Ocular disease; Uveitis

Indexed keywords

ACICLOVIR; INTERFERON; NUCLEOSIDE; TRIFLURIDINE;

AUTOIMMUNITY; BEHCET DISEASE; CELLULAR IMMUNITY; CONJUNCTIVITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; EYE DISEASE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; REVIEW; UVEITIS; VIRUS KERATITIS; VISUAL ACUITY;

ANTINEOPLASTIC AGENTS; EYE DISEASES; HUMANS; IMMUNITY, CELLULAR; INTERFERONS; TREATMENT OUTCOME;

EID: 33750473381     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328010ab35     Document Type: Review

References (59)

1. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005; 204:9-26. Review of the current state of research on the mechanisms by which interferons promote or inhibit autoimmune disease.
2. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005; 252 (Suppl 3):iii3-iii9. Review of clinical trials on interferon-b in the treatment of multiple sclerosis.
3. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-336. In-depth review of current state of basic research on interferons.
4. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71:565-581.
5. Dafny N, Yang PB. Interferon and the central nervous system. Eur J Pharmacol 2005; 523:1-15. Excellent review summarizing the physiological properties and their implications on the brain and the endocrine and immune systems.
6. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25:401-406.
7. Takase H, Futagami Y, Yoshida T, et al. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci 2006; 47:1557-1561. Interesting research paper on associations of local and systemic cytokine levels and uveitis, including interferon.
8. Epplen C, Jackel S, Santos EJ, et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 1997; 41:341-352.
9. Miterski B, Jaeckel S, Epplen JT, et al. Multiple Sclerosis Study Group. The interferon gene cluster: a candidate region for MS predisposition? Genes Immun 1999; 1:37-44.
10. Stanford MR, Vaughan RW, Kondeatis E, et al. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom? Br J Ophthalmol 2005; 89:1013-1016.
11. Akahoshi M, Ishihara M, Remus N, et al. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet 2004; 114:503-509.
12. Cogrel O, Doutre MS, Marliere V, et al. Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br J Dermatol 2002; 146:320-324.
13. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107:133-144.
14. Kotter I, Koch S, Vonthein R, et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a: results of an open study and review of the literature. Clin Exp Rheumatol 2005; 23:S20-S26. Interesting report on cytokine levels in patients with Behcet's disease before and during treatment that sheds light on the intricate mechanisms of interferon action.
15. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106:1431-1442. Detailed review of controlled trials and meta-analysis of different therapeutic options in the adjuvant treatment of high-risk melanoma, comparing among others different interferon regimens.
16. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005; 118:1413.
17. Glue P, Fang JW, Rouzier-Panis R, et al., Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68:556-567.
18. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
19. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005; 239:67-74.
20. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51:682-689.
21. Dhib-Jalbut S. Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 1997; 3:397-401.
22. Satoh J, Paty DW, Kim SU. Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology 1995; 45:367-373.
23. Jiang H, Milo R, Swoveland P, et al. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 1995; 61:17-25.
24. Minagar A, Long A, Ma T, et al. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 2003; 10:299-307.
25. Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005; 89:1254-1257. First report on interferon-β as a treatment for multiple sclerosis-associated uveitis.
26. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005; 76:469-475.
27. Jacobs LD, Beck RW, Simon JH, et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343:898-904.
28. Farel C, Suzman DL, McLaughlin M, et al. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS 2004; 18:1805-1809.
29. D'Alteroche L, Majzoub S, Lecuyer AI, et al. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006; 44:56-61. Prospective study of ophthalmologic side effects in 156 patients receiving interferon with regular ophthalmologic examination before and during treatment.
30. Andrade RJ, Gonzalez FJ, Vazquez L, et al. Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antivir Ther 2006; 11:491-498.
31. Devendra D, Eisenbarth GS. Interferon alpha: a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004; 111:225-233.
32. Brod SA. Ingested type I interferon: a potential treatment for autoimmunity. J Interferon Cytokine Res 2002; 22:1153-1166.
33. Wilhelmus KR. Interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2003; CD002898.
34. Sundmacher R, Cantell K, Mattes A. Combination therapy for dendritic keratitis: high-titer alpha-interferon and trifluridine. Arch Ophthalmol 1984; 102:554-555.
35. Sundmacher R, Neumann-Haefelin D, Shrestha B. The effect of human leukocyte interferon (HIF) on experimental viral keratitis in monkeys (author's transl) [in German]. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1975; 195:263-270.
36. Rossa V, Sundmacher R. Local prevention with interferon of "epidemic" conjunctivitis caused by a currently unidentifiable virus [in German]. Klin Monatsbl Augenheilkd 1991; 199:192-194.
37. Fuchsluger TA, Hintschich C, Steuhl KP, Meller D. Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface. Ophthalmologe 2006; 103:124-128.
38. Boehm MD, Huang AJ. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology 2004; 111:1755-1761.
39. Schechter BA, Schrier A, Nagler RS, et al. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea 2002; 21:6-11.
40. Karp CL, Moore JK, Rosa RH Jr. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology 2001; 108:1093-1098.
41. Kertes PJ, Britton WA Jr, Leonard BC. Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study. Can J Ophthalmol 1997; 32:185-188.
42. Kertes PJ, Britton WA Jr, Addison DJ, et al. Toxicity of intravitreal interferon alpha-2b in the rabbit. Can J Ophthalmol 1995; 30:355-359.
43. Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for longlasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006; 26:786-791. First report on the effectiveness of interferon-α in the treatment of uveitis macular edema.
44. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87:423-431.
45. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138:467-471.
46. Galetta SL. The Controlled High Risk Avonex Multiple Sclerosis Trial (CHAMPS Study). J Neuroophthalmol 2001; 21:292-295.
47. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001; 132:463-471.
48. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990; 322:281-285.
49. Nussenblatt RB, Palestine AG, Chan CC, et al. Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 1985; 28:671-679.
50. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001; 44:2686-2692.
51. Mudun A, Mudun AB, Kocak M, et al. The role of quantitative 99Tcm-glucoheptonate scintigraphy in the evaluation of acute uveitis in patients with Behcet's disease. Nucl Med Commun 1994; 15:178-181.
52. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005; 52:2478-2484.
53. Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986; 278:335-336.
54. Feron EJ, Rothova A, van Hagen PM, et al. Interferon-alpha 2b for refractory ocular Behcet's disease. Lancet 1994; 343:1428.
55. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004; 33:311-319.
56. Calguneri M, Ozturk MA, Ertenli I, et al. Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study. Ann Rheum Dis 2003; 62:492-493.
57. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000; 8:293-301.
58. Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behcet's disease. Adv Exp Med Biol 2003; 528:511-519.
59. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997; 115:865-872.